In our study, we found that type 2 diabetes patients treated with insulin, metformin or a-glucosidase inhibitors had lower circulating sRAGE levels than patients not treated with these agents and that type 2 diabetes patients with CRC had lower rates of medicine use, including insulin, metformin, a-glucosidase inhibitors, thiazolidinedione, NSAIDs and statins, suggesting that insulin, metformin and a-glucosidase inhibitors may protect against CRC mediated by RAGE. This evidence concerns the gene AGER and colorectal carcinoma.